Physicians have launched the world’s first mRNA lung cancer vaccine trial, marking a significant advancement in cancer treatment.
BioNTech developed the vaccine BNT116, which targets non-small cell lung cancer (NSCLC) by training the immune system to identify and attack tumor markers.
Conducted across seven countries, including Türkiye, the phase 1 trial involves 130 patients with varying stages of lung cancer and aims to eliminate cancer cells and prevent recurrence.
The trial uses mRNA technology similar to that in COVID-19 vaccines, potentially offering a less toxic alternative to traditional chemotherapy.
Experts view this trial as a groundbreaking step in cancer research, with the first patient in the UK receiving the vaccine recently.
Source : PhilNews24 | August 24, 2024
WORLD’S INITIAL LUNG CANCER VACCINE TRIAL KICKS OFF
Latest from News
The Office of Civil Defense (OCD) convened national government agencies and uniformed services at the NDRRMC
President Ferdinand Marcos Jr. has directed the Department of Energy (DOE) to restore the country’s power
The Department of Environment and Natural Resources (DENR) Region XI denied claims that President Ferdinand Marcos
The Land Transportation Franchising and Regulatory Board (LTFRB) is eyeing the conversion of around 6,000 traditional
The shrine of St. Padre Pio in Santo Tomas, Batangas, has been officially declared an international